CD1a-Targeted PD-1 Agonists for Localised Immunosuppression in Atopic Dermatitis
- IMC-U120AI is a novel, first in class skin targeted PD-1 agonist bispecific (ImmTAI) to provide localised immune inhibition for the treatment of Atopic Dermatitis
- CD1a-targeted PD-1 agonists show potent inhibition of CD4+T-cells and NK cells
- IMC-U120AI is the first Immunocore ‘universal’ therapy